Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:42:32.598Z.
Calculation as of: 2026-10-06T14:42:32.598Z.
Quote observation: 2026-10-06T14:40:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: eea6c7d5cd6e3fe508f4e89a8ac0afa25f3437e05bd10ab9ad2dfceb562d4ef8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$95.95M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$92.88M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$97.99M
EV/FCF Ratio
N/A
TTM Avg
15.12x
3Y Avg
15.12x
5Y Avg
15.12x
Market Cap
$90.38M
EV/FCF Ratio
22.29x
TTM Avg
56.27x
3Y Avg
59.65x
5Y Avg
59.65x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korro Bio, Inc. (KRRO) | $94.76M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.95M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $92.88M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $97.99M | N/A | 15.12x | 15.12x | 15.12x |
| electroCore, Inc. (ECOR)vs › | $91.24M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $90.38M | 22.29x | 56.27x | 59.65x | 59.65x |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $101.21M | 19.18x | 87.97x | 49.68x | 56.25x |
| Equillium, Inc. (EQ)vs › | $89.15M | N/A | 5.17x | 5.17x | 5.17x |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 5.88x | 5.69x | 5.19x | 9.05x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
